Baseline demographic and disease characteristics
| Baseline characteristic . | High-risk smoldering myeloma (n = 18) . | |
|---|---|---|
| No. . | % . | |
| Median age, y (range) | 59 (40-73) | |
| Sex | ||
| Male | 9 | 50 |
| Female | 9 | 50 |
| Race | ||
| White | 14 | 89 |
| African American | 4 | 11 |
| Risk of progression | ||
| Mayo Clinic risk model* | ||
| High | 3 | 17 |
| Low/intermediate | 15 | 83 |
| Spanish PETHEMA risk model† | ||
| High | 16 | 89 |
| Low/intermediate | 2 | 11 |
| MM by the 2014 IMWG criteria11 | 6 | 33 |
| Heavy chain isotype | ||
| IgG | 16 | 89 |
| IgA | 1 | 5.5 |
| Light chain | 1 | 5.5 |
| Light chain isotype | ||
| κ | 13 | 72 |
| Λ | 5 | 28 |
| FISH/cytogenetics | ||
| 13q14 deletion | 4 | 22 |
| 17p13.1 deletion | 1 | 6 |
| IgH translocation | 4 | 22 |
| Median serum monoclonal protein, g/dL (range) | 1.9 (1.0-5.3) | |
| Bone marrow plasma cell infiltration | ||
| Median, % (range) | 30 (12.5-65) | |
| 10-60 | 12 | 67 |
| >60 | 6 | 33 |
| Baseline characteristic . | High-risk smoldering myeloma (n = 18) . | |
|---|---|---|
| No. . | % . | |
| Median age, y (range) | 59 (40-73) | |
| Sex | ||
| Male | 9 | 50 |
| Female | 9 | 50 |
| Race | ||
| White | 14 | 89 |
| African American | 4 | 11 |
| Risk of progression | ||
| Mayo Clinic risk model* | ||
| High | 3 | 17 |
| Low/intermediate | 15 | 83 |
| Spanish PETHEMA risk model† | ||
| High | 16 | 89 |
| Low/intermediate | 2 | 11 |
| MM by the 2014 IMWG criteria11 | 6 | 33 |
| Heavy chain isotype | ||
| IgG | 16 | 89 |
| IgA | 1 | 5.5 |
| Light chain | 1 | 5.5 |
| Light chain isotype | ||
| κ | 13 | 72 |
| Λ | 5 | 28 |
| FISH/cytogenetics | ||
| 13q14 deletion | 4 | 22 |
| 17p13.1 deletion | 1 | 6 |
| IgH translocation | 4 | 22 |
| Median serum monoclonal protein, g/dL (range) | 1.9 (1.0-5.3) | |
| Bone marrow plasma cell infiltration | ||
| Median, % (range) | 30 (12.5-65) | |
| 10-60 | 12 | 67 |
| >60 | 6 | 33 |
FISH, fluorescent in situ hybridization; Ig, immunoglobulin.
High-risk features include bone marrow plasma cell infiltration >10%, serum monoclonal protein >3 g/dL, and free light chain ratio >8 or <0.125.
High-risk features include 95% or more plasma cells with abnormal immunophenotype by flow cytometry and serum immunoparesis.